{"product_id":"hzkangji-pestle-analysis","title":"Hangzhou Kangji Medical Equipment PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a competitive edge with our focused PESTLE Analysis of Hangzhou Kangji Medical Equipment—revealing how political shifts, economic trends, social demands, technological advances, legal risks, and environmental pressures will shape its outlook; buy the full report to access actionable insights, ready-to-use slides, and data that power smarter investment and strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Infrastructure Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025 the Healthy China 2030 drive channels over CNY 1.2 trillion into healthcare infrastructure, prioritizing OR modernization across urban and rural hospitals; this fuels annual public procurement growth of ~8–10%. Kangji Medical captured about 4.3% of state-led hospital equipment tenders in 2024–25, benefiting from repeat purchases of surgical pendants and essential OR hardware worth ~CNY 420–480 million annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLocalization and Import Substitution Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational policies increasingly favor domestic medical device makers to secure supply chains, with China’s 2024 procurement rules raising domestic preference thresholds to roughly 30–50% in public tenders and local content incentives worth up to CNY 200m annually in some provinces.\u003c\/p\u003e\n\u003cp\u003eThis buy-local trend gives Hangzhou firms like Kangji an edge in government tenders, where domestic suppliers won 62% of high-value device contracts in 2023.\u003c\/p\u003e\n\u003cp\u003eKangji has leveraged incentives and localization to capture share from foreign high-end brands, growing revenue 28% in FY2024 and increasing its domestic market share in diagnostic equipment by an estimated 4–6 percentage points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized Volume-Based Procurement Impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCentralized volume-based procurement, while focused on consumables, has driven a 6-8% downward pressure on hospital capital budgets in China since 2023, pushing suppliers to cut equipment prices; regulators now require public competitive tenders for \u0026gt;¥5 million installations, increasing bid transparency and lowering margins. Kangji Medical must balance these pricing constraints with compliance to National Medical Products Administration quality standards and recent provincial tenders showing price reductions up to 12%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOngoing trade tensions and export controls between major economies have tightened access to semiconductor-dependent medical devices, with global medical device trade growth slowing to 1.8% in 2024; Kangji Medical faces elevated risk from fluctuating tariffs and divergent certification regimes in the US, EU and China.\u003c\/p\u003e\n\u003cp\u003eAs an exporter, Kangji must budget for potential tariff swings—recent average tariff shifts of 2–4 percentage points—and increased compliance costs, which can add 1–2% to COGS for regulated devices.\u003c\/p\u003e\n\u003cp\u003eThe company is prioritizing Belt and Road markets, where 2024 healthcare spending in BRI countries rose about 6.5%, to diversify political and economic exposure and target revenue growth outside Western markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrade tensions slowed global med-tech trade growth to 1.8% in 2024\u003c\/li\u003e\n\u003cli\u003eTariff volatility adds ~2–4 pp risk; compliance can raise COGS by 1–2%\u003c\/li\u003e\n\u003cli\u003eBRI healthcare spending grew ~6.5% in 2024; strategic market diversification ongoing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth and Safety Regulatory Oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical stability in China ensures consistent oversight by the National Medical Products Administration, which in 2024 issued over 18,000 medical device registrations, supporting predictable regulation for Kangji Medical.\u003c\/p\u003e\n\u003cp\u003eRecent government mandates raising surgical safety standards—part of a 2023–25 policy push reducing hospital adverse events by 12% nationally—boost demand for integrated operating room solutions.\u003c\/p\u003e\n\u003cp\u003eKangji aligns R\u0026amp;D and product roadmaps with national safety priorities, investing ~RMB 120 million in compliant OR systems in 2024 to secure long-term policy support.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable regulation via NMPA: 18,000+ device registrations (2024)\u003c\/li\u003e\n\u003cli\u003ePolicy impact: 12% reduction in hospital adverse events (2023–25 target)\u003c\/li\u003e\n\u003cli\u003eKangji investment: ~RMB 120 million in OR systems (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKangji rides Healthy China, gains 4.3% tenders and 28% revenue amid margin pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical support via Healthy China and buy-local rules drove Kangji’s FY2024–25 tender share to ~4.3% and revenue +28%; domestic-preference thresholds rose to 30–50% and provincial incentives reached ~CNY200m. Centralized procurement trimmed hospital capital budgets 6–8%, pressuring margins; tariff volatility (±2–4 pp) and compliance add ~1–2% to COGS.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTender share (2024–25)\u003c\/td\u003e\n\u003ctd\u003e4.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue growth FY2024\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic preference\u003c\/td\u003e\n\u003ctd\u003e30–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital capex pressure\u003c\/td\u003e\n\u003ctd\u003e-6–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff volatility\u003c\/td\u003e\n\u003ctd\u003e±2–4 pp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance COGS impact\u003c\/td\u003e\n\u003ctd\u003e+1–2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Hangzhou Kangji Medical Equipment across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to identify threats and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise PESTLE snapshot of Hangzhou Kangji Medical Equipment, organized by political, economic, social, technological, legal, and environmental factors to quickly flag external risks and strategic opportunities for meetings or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Healthcare Expenditure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina's healthcare spending rose to about 7.8% of GDP by 2024 and trended upward into 2025–2026, driven by aging demographics and policy investment; this expansion enables hospitals to increase capital expenditure on high-value devices such as medical pendants and advanced operating tables. Kangji Medical benefits as domestic providers redeploy larger budgets toward premium equipment, boosting order sizes and supporting higher-margin product adoption across tier-2 and tier-3 hospitals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Efficiency in Surgical Procedures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEconomic pressures on Chinese hospital budgets—public hospital funding growth slowed to 3.8% in 2024—heighten demand for integrated OR solutions that boost theater turnover and cut per-case costs.\u003c\/p\u003e\n\u003cp\u003eHangzhou Kangji’s integrated operating-room systems, priced competitively versus fragmented sourcing, claim up to 15–25% lower total procurement and maintenance costs in pilot contracts.\u003c\/p\u003e\n\u003cp\u003eClinical customers report surgical downtime reductions of 12–20%, translating to estimated annual savings of RMB 1.2–2.5 million for mid-sized tertiary hospitals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Fluctuation and Export Competitiveness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRenminbi volatility through 2025 — swinging about 6.8–7.2 CNY\/USD in H1 2025 — directly alters Hangzhou Kangji Medical’s export pricing: a weaker RMB improves price competitiveness in emerging markets, while a stronger RMB compresses margins on imported raw materials (imports ~28% of COGS in 2024). The firm uses currency hedges and forward contracts covering roughly 60% of FX exposure to stabilize margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of Private Healthcare Sector\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe expansion of private hospital groups and specialized surgical centers in China, growing at about 12% CAGR 2019–2024 and accounting for ~30% of inpatient revenue by 2024, creates a secondary economic engine for medical device demand.\u003c\/p\u003e\n\u003cp\u003ePrivate entities prioritize modern, integrated ORs to attract premium patients and high-tier surgeons; average OR upgrade projects now cost RMB 2–5 million each.\u003c\/p\u003e\n\u003cp\u003eKangji Medical targets this segment to diversify revenue beyond public tenders, aiming for 25–35% private-sales share by 2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrivate hospitals CAGR ~12% (2019–2024)\u003c\/li\u003e\n\u003cli\u003e~30% inpatient revenue from private sector (2024)\u003c\/li\u003e\n\u003cli\u003eOR upgrade cost RMB 2–5 million\u003c\/li\u003e\n\u003cli\u003eKangji private-sales target 25–35% by 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Labor Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cprising labor costs in the yangtze river delta rose about year-on-year pushing kangji medical to invest automation hangzhou protect margins capex on plant upgrades approximately vs accelerate efficiency gains.\u003e\n\u003cpkangji reports process optimization and workforce upskilling initiatives that reduced unit labor cost by an estimated in h1 helping offset wage inflation input-price pressures.\u003e\n\u003cpmaintaining a lean cost structure gross margin improvement of basis points crucial to compete with domestic rivals and global oems amid tightening margins.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eYangtze River Delta wages +6.5% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eKangji capex on automation +12% (2024)\u003c\/li\u003e\n\u003cli\u003eUnit labor cost down ~4% (H1 2025)\u003c\/li\u003e\n\u003cli\u003eGross margin target +150–200 bps\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pmaintaining\u003e\u003c\/pkangji\u003e\u003c\/prising\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina healthcare: private surge, automation offsets wage rise; imports and FX pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealthcare spend ~7.8% GDP (2024), public hospital funding +3.8% (2024); private hospitals CAGR ~12% (2019–24) and ~30% inpatient revenue (2024); Kangji targeting 25–35% private sales by 2026; imports ~28% of COGS (2024); RMB 6.8–7.2 CNY\/USD (H1 2025); wages +6.5% YoY (Yangtze Delta, 2024); automation capex +12% (2024), unit labor cost -4% (H1 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare spend\u003c\/td\u003e\n\u003ctd\u003e7.8% GDP (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic hospital funding\u003c\/td\u003e\n\u003ctd\u003e+3.8% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate hospitals\u003c\/td\u003e\n\u003ctd\u003e12% CAGR (2019–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate inpatient share\u003c\/td\u003e\n\u003ctd\u003e~30% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImports of COGS\u003c\/td\u003e\n\u003ctd\u003e~28% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMB FX\u003c\/td\u003e\n\u003ctd\u003e6.8–7.2 CNY\/USD (H1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWage inflation\u003c\/td\u003e\n\u003ctd\u003e+6.5% YoY (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomation capex\u003c\/td\u003e\n\u003ctd\u003e+12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnit labor cost\u003c\/td\u003e\n\u003ctd\u003e-4% (H1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eHangzhou Kangji Medical Equipment PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Hangzhou Kangji Medical Equipment PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752099983737,"sku":"hzkangji-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/hzkangji-pestle-analysis.png?v=1772237571","url":"https:\/\/matrixbcg.com\/products\/hzkangji-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}